EP1539793A4 - Anticorps humanises diriges contre le recepteur de la lymphotoxine beta - Google Patents

Anticorps humanises diriges contre le recepteur de la lymphotoxine beta

Info

Publication number
EP1539793A4
EP1539793A4 EP03762296A EP03762296A EP1539793A4 EP 1539793 A4 EP1539793 A4 EP 1539793A4 EP 03762296 A EP03762296 A EP 03762296A EP 03762296 A EP03762296 A EP 03762296A EP 1539793 A4 EP1539793 A4 EP 1539793A4
Authority
EP
European Patent Office
Prior art keywords
humanized anti
receptor antibodies
beta receptor
lymphotoyin
lymphotoyin beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03762296A
Other languages
German (de)
English (en)
Other versions
EP1539793A2 (fr
Inventor
Ellen Garber
Kenneth Simon
Jose Saldanha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of EP1539793A2 publication Critical patent/EP1539793A2/fr
Publication of EP1539793A4 publication Critical patent/EP1539793A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP03762296A 2002-07-01 2003-07-01 Anticorps humanises diriges contre le recepteur de la lymphotoxine beta Withdrawn EP1539793A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US39299302P 2002-07-01 2002-07-01
US392993P 2002-07-01
US41737202P 2002-10-09 2002-10-09
US417372P 2002-10-09
PCT/US2003/020762 WO2004002431A2 (fr) 2002-07-01 2003-07-01 Anticorps humanises diriges contre le recepteur de la lymphotoxine beta

Publications (2)

Publication Number Publication Date
EP1539793A2 EP1539793A2 (fr) 2005-06-15
EP1539793A4 true EP1539793A4 (fr) 2006-02-01

Family

ID=30003289

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03762296A Withdrawn EP1539793A4 (fr) 2002-07-01 2003-07-01 Anticorps humanises diriges contre le recepteur de la lymphotoxine beta

Country Status (10)

Country Link
US (1) US7429645B2 (fr)
EP (1) EP1539793A4 (fr)
JP (1) JP2005532051A (fr)
CN (1) CN1678625A (fr)
AR (1) AR040367A1 (fr)
AU (1) AU2003248782A1 (fr)
CA (1) CA2491480A1 (fr)
NZ (1) NZ537965A (fr)
TW (1) TW200416044A (fr)
WO (1) WO2004002431A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
IL142284A0 (en) * 1998-10-09 2002-03-10 Biogen Inc A pharmaceutical composition containing an agent which blocks the binding of lymphotoxin-b to its receptor
TR200300478T2 (tr) * 2000-10-13 2004-10-21 Biogen Inc. Hümanize antiLT-ß-R antikorları
WO2004058191A2 (fr) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Agonistes multivalents de recepteur beta de lymphotoxine et leurs applications therapeutiques
RS20050481A (sr) * 2002-12-20 2007-08-03 Biogen Idec Ma Inc., Agensi limfotoksin beta receptora u kombinaciji sa hemoterapeutskim agensima
US7700097B2 (en) * 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
JP2005241389A (ja) * 2004-02-25 2005-09-08 Ochiyanomizu Jiyoshi Univ 蛍光標識糖鎖の特異的固定化試薬および固定化方法
BRPI0509201A (pt) * 2004-03-23 2007-08-28 Biogen Idec Inc agentes de acoplamento de receptor e usos terapêuticos destes
WO2006074399A2 (fr) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Molecules de liaison multispecifiques comprenant des peptides de connexion
US20120282245A1 (en) 2006-10-03 2012-11-08 Biogen Idec Ma Inc. Biomarkers and assays for the treatment of cancer
NZ576032A (en) 2006-10-12 2012-03-30 Genentech Inc Antibodies to lymphotoxin-alpha
SG178002A1 (en) * 2006-10-20 2012-02-28 Biogen Idec Inc Treatment of demyelinating disorders
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
DK2158315T3 (en) 2007-06-25 2016-06-06 Esbatech Alcon Biomed Res Unit Methods of modifying antibodies and modified antibodies with improved functional properties
EP2382238A1 (fr) * 2008-12-31 2011-11-02 Biogen Idec MA Inc. Anticorps anti-lymphotoxine
US8481688B2 (en) * 2010-05-11 2013-07-09 Aveo Pharmaceuticals, Inc. Anti-FGFR2 antibodies
TWI897855B (zh) * 2018-10-26 2025-09-21 美商免疫遺傳股份有限公司 Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途
AU2020401755A1 (en) * 2019-12-11 2022-08-04 Cilag Gmbh International Multispecific binding molecules comprising LTBR and EDB binding domains and uses thereof
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
CR20240246A (es) * 2021-12-20 2024-07-19 Hoffmann La Roche Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
WO2023218320A1 (fr) * 2022-05-11 2023-11-16 Pfizer Inc. Anticorps anti-récepteur de la lymphotoxine bêta et leurs procédés d'utilisation
WO2025012620A1 (fr) 2023-07-07 2025-01-16 Mestag Therapeutics Ltd Constructions de liaison
EP4527851A1 (fr) 2023-09-22 2025-03-26 Bayer Aktiengesellschaft Anticorps bispécifiques se liant à ltbr et lrrc15
WO2025172587A1 (fr) 2024-02-16 2025-08-21 Mestag Therapeutics Ltd Constructions de liaison
WO2025172588A1 (fr) 2024-02-16 2025-08-21 Mestag Therapeutics Ltd Constructions bispécifiques dirigées contre fap et ltbr
WO2025221736A2 (fr) 2024-04-15 2025-10-23 Janssen Biotech, Inc. Molécules de liaison à ltbr et leurs utilisations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU692146B2 (en) 1990-06-27 1998-06-04 Biogen Idec Ma Inc. Lymphotoxin-beta, lymphotoxin-beta complexes, pharmaceutical preparations and therapeutic uses thereof
ES2157889T3 (es) 1990-06-27 2001-09-01 Biogen Inc Linfotoxina complejada de superficie.
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
WO1996022788A1 (fr) * 1995-01-26 1996-08-01 Biogen, Inc. COMPLEXES DE LYMPHOTOXINE-α/β ET ANTICORPS DE RECEPTEUR ANTI-LYMPHOTOXINE-BETA UTILES EN TANT QU'AGENTS ANTI-TUMORAUX
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
CZ301026B6 (cs) 1998-01-30 2009-10-14 Biogen Idec Ma Inc. Použití kompozice inhibující interakci LT-ß a jeho receptoru pro výrobu prípravku k lécení folikulárního lymfomu
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
GB9809839D0 (en) * 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
TR200300478T2 (tr) 2000-10-13 2004-10-21 Biogen Inc. Hümanize antiLT-ß-R antikorları
WO2004058191A2 (fr) 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Agonistes multivalents de recepteur beta de lymphotoxine et leurs applications therapeutiques
RS20050481A (sr) 2002-12-20 2007-08-03 Biogen Idec Ma Inc., Agensi limfotoksin beta receptora u kombinaciji sa hemoterapeutskim agensima
BRPI0509201A (pt) 2004-03-23 2007-08-28 Biogen Idec Inc agentes de acoplamento de receptor e usos terapêuticos destes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BROWNING J ET AL: "CHARACTERIZATION OF SURFACE LYMPHOTOXIN FORMS. USE OF SPECIFIC MONOCLONAL ANTIBODIES AND SOLUBLE RECEPTORS", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 154, no. 1, January 1995 (1995-01-01), pages 33 - 46, XP002018575, ISSN: 0022-1767 *
BROWNING J L ET AL: "SIGNALING THROUGH THE LYMPHOTOXIN BETA RECEPTOR INDUCES THE DEATH OF SOME ADENOCARCINOMA TUMOR LINES", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 183, no. 3, 1 March 1996 (1996-03-01), pages 867 - 878, XP000571445, ISSN: 0022-1007 *

Also Published As

Publication number Publication date
TW200416044A (en) 2004-09-01
JP2005532051A (ja) 2005-10-27
US20060222644A1 (en) 2006-10-05
EP1539793A2 (fr) 2005-06-15
US7429645B2 (en) 2008-09-30
AR040367A1 (es) 2005-03-30
WO2004002431A3 (fr) 2004-08-26
CA2491480A1 (fr) 2004-01-08
CN1678625A (zh) 2005-10-05
NZ537965A (en) 2008-04-30
WO2004002431A2 (fr) 2004-01-08
AU2003248782A1 (en) 2004-01-19

Similar Documents

Publication Publication Date Title
AU2003264009A8 (en) Humanized rabbit antibodies
AU2003259294A8 (en) Humanized antibodies against human 4-1bb
IL163626A0 (en) Humanized antibodies that recognize beta amyloid peptide
IL168304A (en) Human monoclonal antibodies against cd25
EP1494693A4 (fr) Anticorps specifiques au cripto
IL243914A0 (en) Antibodies against vegf
EP1567541A4 (fr) Anticorps elabores de maniere rationnelle
PL375405A1 (en) Antibodies
IL202348A0 (en) Anti-her2 antibody variants
IL166244A0 (en) Super humanized antibodies
AU2003285540A8 (en) Antibody for the thyrotropin receptor and uses thereof
AU2003257032A8 (en) Antibodies against c3a receptor
AU2003277832A8 (en) Humanized tissue factor antibodies
IL163580A0 (en) Assay for anti-ingap antibodies
AU2003229799A1 (en) Novel humanized anti-vap-1 monoclonal antibody
EP1692176A4 (fr) Anticorps du recepteur anti-igf-i
GB0226878D0 (en) Antibodies
HK1074845A (en) Humanized anti-lymphotoyin beta receptor antibodies
AU2003226764A8 (en) Novel glucocorticoid receptor ligands
GB0215389D0 (en) Receptor
AU2003236346A1 (en) Monoclonal antibody neutralizing megsin
IL165753A0 (en) Humanized monoclonal antibody nPAM4
GB0325391D0 (en) Human monoclonal antibodies
EP1575917A4 (fr) Recepteur muscarinique d'hemipteres
GB0218230D0 (en) Antibodies

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050201

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1074845

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20051215

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOGEN IDEC MA INC.

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/395 20060101ALI20050208BHEP

Ipc: C07K 16/00 20060101ALI20050208BHEP

Ipc: C12N 5/12 20060101ALI20050208BHEP

Ipc: C07K 16/28 20060101AFI20051209BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080716

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1074845

Country of ref document: HK